Literature DB >> 7979156

Two loci for tuberous sclerosis: one on 9q34 and one on 16p13.

S Povey1, M W Burley, J Attwood, F Benham, D Hunt, S J Jeremiah, D Franklin, G Gillett, S Malas, E B Robson.   

Abstract

32 families informative for the segregation of Tuberous sclerosis (TSC) have been examined for genetic markers on chromosomes 9, 11, 12 and 16. In one large family there was clear evidence of linkage to markers on chromosome 16p13.3 (lodscore with D16S291 of 4.7 at theta = 0) but other families were too small to give individually convincing lodscores. Combined results for all families gave positive results with ABO/DBH on chromosome 9 (max lod 2.63) and with D16S291 on chromosome 16 (max lod 3.98) at values of theta of 0.2 in each case. Further analysis showed strong evidence for heterogeneity with approximately half the families linked to a locus TSC1 on chromosome 9 between ASS and D9S298 and half to TSC2 on chromosome 16 close to D16S291. There was no definite support for a third locus although in many families this could not be excluded. In three families the segregation pattern of TSC remains unexplained. In two of these the family apparently segregates for TSC1 but in each case a single affected individual appeared to exclude the whole of the candidate region. Preliminary analysis of clinical features did not reveal any definite differences in incidence of mental handicap between individuals in different linkage groups or with different sex of the parent of origin. The frequencies of periungual fibromas and facial angiofibromas were also similar in both linkage groups. The difficulties of detecting linkage in small families where there is locus heterogeneity are discussed. The program ZZ was found to be helpful in this respect.

Entities:  

Mesh:

Year:  1994        PMID: 7979156     DOI: 10.1111/j.1469-1809.1994.tb01881.x

Source DB:  PubMed          Journal:  Ann Hum Genet        ISSN: 0003-4800            Impact factor:   1.670


  37 in total

Review 1.  Imaging of single DNA molecule: applications to high-resolution genomic studies.

Authors:  J Herrick; A Bensimon
Journal:  Chromosome Res       Date:  1999       Impact factor: 5.239

2.  Tuberous sclerosis.

Authors:  F J O'Callaghan
Journal:  BMJ       Date:  1999-04-17

3.  Proteomic approach for the elucidation of biological defects in autism.

Authors:  M A Junaid; R K Pullarkat
Journal:  J Autism Dev Disord       Date:  2001-12

4.  Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation.

Authors:  M van Slegtenhorst; S Verhoef; A Tempelaars; L Bakker; Q Wang; M Wessels; R Bakker; M Nellist; D Lindhout; D Halley; A van den Ouweland
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

5.  Medical disorders among inpatients with autism in Denmark according to ICD-8: a nationwide register-based study.

Authors:  Marlene B Lauritsen; Ole Mors; Preben B Mortensen; Henrik Ewald
Journal:  J Autism Dev Disord       Date:  2002-04

6.  Papillary thyroid carcinoma in a boy with familial tuberous sclerosis complex attributable to a TSC2 deletion-a case report.

Authors:  M Flader; P Kurzawa; J Maldyk; J Sygut; J Harasymczuk; A Kropinska; D Handkiewicz-Junak; B Jarzab; K Kotulska; M Niedziela
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

Review 7.  Neurological manifestations of tuberous sclerosis complex.

Authors:  P Curatolo
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

8.  Mutations in the TSC1 gene account for a minority of patients with tuberous sclerosis.

Authors:  J B Ali; T Sepp; S Ward; A J Green; J R Yates
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

9.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.

Authors:  T Soucek; R S Yeung; M Hengstschläger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 10.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.